This is a depiction of Kaplan-Meier survival curve with genomically targeted agents
(blue line) as compared to standard therapies (purple line), indicating an
improvement in median overall survival but lack of durable responses;
improved median overall survival and durable responses in a fraction of
patients treated with immune checkpoint therapy (green line); possibility for
improved median overall survival with durable responses for the majority of
patients in the setting of combination treatment with genomically targeted
agents and immune checkpoint therapy (red line).